deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04646395

Study of Acalabrutinib and Tafasitamab in MZL Patients

Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)

Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Conditions Marginal Zone Lymphoma
Interventions Acalabrutinib Tafasitamab
Updated 18 times since 2020 Last updated: Jan 29, 2025 Started: Oct 20, 2021 Primary completion: Sep 15, 2027 Completion: Mar 15, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Marginal Zone Lymphoma, this trial is ongoing. The trial is conducted by International Extranodal Lymphoma Study Group (IELSG) and has accumulated 18 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 13 earlier versions

  1. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jun 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  3. Dec 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  5. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  6. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  7. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  8. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  9. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Sep 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

  12. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

  13. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • International Extranodal Lymphoma Study Group (IELSG)
Data source: International Extranodal Lymphoma Study Group (IELSG)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations